{"cdcTestId":"2013-0507","testcaseName":"# 1 at age 11 years","vaccineGroup":"MCV","evaluationTestType":"Age: At Minimum","forecastTestType":"Recommended based on age","assessmentDate":"2022-10-19T00:00:00","patient":{"dob":"2011-10-19T00:00:00","gender":"F"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"meningococcal MCV4, unspecified formulation","cvx":"147","mvx":"","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"2","earliestDate":"2027-10-19T00:00:00","recommendedDate":"2027-10-19T00:00:00","pastDueDate":"2028-11-15T00:00:00"},"doses":[{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"meningococcal MCV4, unspecified formulation","cvx":"147","mvx":"","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2013-01-01T00:00:00","dateUpdated":"2017-11-15T07:31:49.848","generalDescription":"This test case describes when dose #1 of a Mening vaccine is administered at age 11 years \u002B 0 days that the dose is considered to be valid.  ","changedInVersion":"1.6","reasonForChange":"v1.6: An EIPB clarification has resulted in a change to when dose 2 of MCV should be forecasted and validated.  The second dose must come on or after 16 years (- 4 days) of age to be considered valid."}